Durbin Matthew D, Helvaty Lindsey R, Li Ming, Border William, Fitzgerald-Butt Sara, Garg Vidu, Geddes Gabrielle C, Helm Benjamin M, Lalani Seema R, McBride Kim L, McEntire Alexis, Mitchell Dana K, Murali Chaya N, Wechsler Stephanie B, Landis Benjamin J, Ware Stephanie M
Indiana University School of Medicine, Indianapolis, IN.
Emory University School of Medicine, Atlanta, GA.
Genet Med Open. 2023 Apr 29;1(1):100814. doi: 10.1016/j.gimo.2023.100814. eCollection 2023.
For patients with congenital heart disease (CHD), the most common birth defect, genetic evaluation is not universally accepted, and current practices are anecdotal. Here, we analyzed genetic evaluation practices across centers, determined diagnostic yield of testing, and identified phenotypic features associated with abnormal results.
This is a multicenter cross-sectional study of 5 large children's hospitals, including 2899 children ≤14 months undergoing surgical repair for CHD from 2013 to 2016, followed by multivariate logistics regression analysis.
Genetic testing occurred in 1607 of 2899 patients (55%). Testing rates differed highly between institutions (42%-78%, < .001). Choice of testing modality also differed across institutions (ie, chromosomal microarray, 26%-67%, < .001). Genetic testing was abnormal in 702 of 1607 patients (44%), and no major phenotypic feature drove diagnostic yield. Only 849 patients were seen by geneticists (29%), ranging across centers (15%-52%, < .001). Geneticist consultation associated with increased genetic testing yield (odds ratio: 5.7, 95% CI 4.33-7.58, < .001).
Genetics evaluation in CHD is diagnostically important but underused and highly variable, with high diagnostic rates across patient types, including in infants with presumed isolated CHD. These findings support recommendations for comprehensive testing and standardization of care.
先天性心脏病(CHD)是最常见的出生缺陷,目前基因评估尚未被广泛接受,且当前实践多为个案。在此,我们分析了各中心的基因评估实践,确定检测的诊断率,并识别与异常结果相关的表型特征。
这是一项对5家大型儿童医院的多中心横断面研究,纳入了2013年至2016年期间接受CHD手术修复的2899名14个月及以下儿童,随后进行多因素逻辑回归分析。
2899例患者中有1607例(55%)进行了基因检测。各机构之间的检测率差异很大(42%-78%,P<0.001)。检测方式的选择在各机构之间也有所不同(即染色体微阵列,26%-67%,P<0.001)。1607例患者中有702例(44%)基因检测结果异常,且没有主要表型特征能驱动诊断率。只有849例患者接受了遗传学家的诊治(29%),各中心的比例不同(15%-52%,P<0.001)。遗传学家会诊与基因检测阳性率增加相关(优势比:5.7,95%CI 4.33-7.58,P<0.001)。
CHD的基因评估在诊断上很重要,但未得到充分利用且差异很大,在各类患者中诊断率都很高,包括疑似单纯CHD的婴儿。这些发现支持了全面检测和护理标准化的建议。